RankAlpha logo
Back to Rankings

BIO

Bio-Rad LaboratoriesD
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that core operations are proving more durable than the headline GAAP loss suggests: Q1 reported sales still grew, Bio-Rad remained cash generative, repurchased shares, and activist involvement may sharpen capital-allocation discipline.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Academic research demand remains soft, especially in the Americas, pressuring constant-currency Life Science growth. [#SEC-8K-2026-04-30]
Momentum
28
Value
64
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $305.00 · Bull $340.00 · Bear $245.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $301.25
Why
Momentum28 · Δ7d +2.7
Value64 · Δ7d -0.4
Sentiment45 · Δ7d -6.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
28
26% active weight
Current posture
7d trendSoftening
Δ7d
+2.7
Δ21d
-7.8
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.0
Sentiment
45
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.3
Δ21d
-2.9
Why this grade

Composite grade D. Momentum 28.4 / Value 63.9 / Sentiment 44.8

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$8.19B
Beta
1.18
Shares Out
26.76M
P/E (TTM)
27.2
P/S (TTM)
3.38
P/FCF (TTM)
25.65
Rev YoY
+1.1%
EPS YoY
-954.0%
Gross Margin
+51.8%
Op Margin
+8.5%
Net Debt
-$157.4M
Current Ratio
3.21
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology